<DOC>
	<DOCNO>NCT02610127</DOCNO>
	<brief_summary>The overall objective enroll patient acquire hemophilia A ( AHA ) prescribe treated Obizur , ass safety , describe factor related safety , utilization effectiveness real-world setting .</brief_summary>
	<brief_title>Post-Marketing Non-Interventional Safety Evaluation Obizur Treatment Bleeding Episodes Patients With Acquired Hemophilia A</brief_title>
	<detailed_description>This study multi-center , uncontrolled , open-label , non-interventional post-marketing safety surveillance study describe use Obizur patient acquire hemophilia A ( AHA ) , secondarily , data available , describe hemostatic effectiveness immunogenicity Obizur . Patients enrol early possible time point , within ten day initiate Obizur ensure unbiased prospective observation . In addition , attempt collect safety utilization data patient treat Obizur since Food Drug Administration approval , Baxalta conduct retrospective chart review person treat Obizur prior prospective study start date ( Retrospective study participant may may also participate prospective portion study ) .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Participant â‰¥18 year age time informed consent . 2 . Participant AHA , treated/was treat Obizur . 3 . Participant willing able provide inform consent , unless inform consent require 1 . Participant know anaphylactic reaction active substance , excipients , hamster protein . 2 . Participant concomitant bleeding disorder ( ) acquire hemophilia A ( AHA ) . 3 . Participant participate another clinical study involve medicinal product device within 30 day prior enrollment schedule participate another clinical study involve medicinal product device course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>